The Effect of ACEI/ARB on the Outcomes of COVID-19 Hospitalized Patients

Simple item page
AuthorTahereh Sabaghianen
AuthorMinoo Heidari Almasien
AuthorFarzaneh Futuhien
AuthorMinoosh Shabanien
AuthorAzam Erfanifaren
AuthorSeyed Alireza Ebadien
OrcidTahereh Sabaghian [0000-0001-7689-8150]en
OrcidMinoo Heidari Almasi [0000-0001-8058-6467]en
OrcidMinoosh Shabani [0000-0002-4064-8325]en
OrcidAzam Erfanifar [0000-0002-9530-0860]en
Issued Date2022-05-31en
AbstractConsidering that there are different reports about the effects of angiotensin II type-I receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI) on the outcomes of the patients with COVID-19, we aimed to conduct this retrospective study on 138 hypertensive patients (81 ACEI/ARB users) to assess the patients’ outcomes by comparing ACEI/ARB and non-ACEI/ARB users. Multivariate adjusted cox regression model, by considering the effect of other variables, demonstrated that increased age (HR = 1.04, 95% CI = 1.01 -1.07, P =0.003) and non- ACEI/ARB users (HR = 2.12 95% CI = 1.12 - 4.13, P = 0.021) were associated with increased risk of in-hospital mortality in about one week follow-up. In conclusion, we found that in-hospital mortality was lower in ACEI/ARB users, showing the positive effect of these treatments on patients’ outcomes.en
DOIhttps://doi.org/10.5812/numonthly-121819en
URIhttps://brieflands.com/journals/num/articles/121819en
KeywordCOVID-19en
KeywordHypertensionen
KeywordMortalityen
KeywordAngiotensin-converting Enzyme Inhibitoren
KeywordAngiotensin Receptor Blockersen
PublisherBrieflandsen
TitleThe Effect of ACEI/ARB on the Outcomes of COVID-19 Hospitalized Patientsen
TypeBrief Reporten

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
num-14-2-121819.pdf
Size:
93.65 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF
Download

Collections

Nephro-Urology Monthly